{"id":"integral-ticagrelor","safety":{"commonSideEffects":[{"rate":"3-5","effect":"Bradycardia"},{"rate":"4-6","effect":"Dyspnea"},{"rate":"4-11","effect":"Bleeding"},{"rate":"2-4","effect":"Ventricular pauses"}]},"_chembl":{"chemblId":"CHEMBL398435","moleculeType":"Small molecule","molecularWeight":"522.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ticagrelor binds directly and reversibly to the P2Y12 adenosine diphosphate (ADP) receptor on platelets, blocking platelet activation and aggregation. This antiplatelet effect reduces the formation of blood clots and is used to prevent cardiovascular events in acute coronary syndromes and other thrombotic conditions. The 'integral' formulation likely refers to an extended-release or optimized formulation of the standard ticagrelor molecule.","oneSentence":"Ticagrelor is a P2Y12 platelet receptor antagonist that inhibits platelet aggregation and reduces thrombotic events.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:49:16.571Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (ACS)"},{"name":"Secondary prevention of thrombotic cardiovascular events"}]},"trialDetails":[{"nctId":"NCT03708588","phase":"PHASE4","title":"Chewed Versus Integral Pill of Ticagrelor","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2018-09-19","conditions":"Percutaneous Coronary Intervention","enrollment":112},{"nctId":"NCT04567290","phase":"PHASE4","title":"Pharmacodynamic Evaluation of Antiplatelet Effect of Swallowing Versus Chewing Ticagrelor in Patients With Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"Centro Hospitalario La Concepcion","startDate":"2020-10-07","conditions":"Acute Coronary Syndrome","enrollment":50},{"nctId":"NCT02612116","phase":"PHASE4","title":"Comparison of Administration Strategies of Ticagrelor in Patients With Unstable Angina Pectoris, a Pharmacokinetic / Pharmacodynamic Study","status":"COMPLETED","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2015-09","conditions":"Unstable Angina Pectoris","enrollment":49},{"nctId":"NCT01992523","phase":"PHASE3","title":"Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )","status":"COMPLETED","sponsor":"David Antoniucci","startDate":"2013-11","conditions":"Acute Coronary Syndrome, Adverse Reaction to Antiplatelet Agent","enrollment":82}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":95,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Brilique"],"phase":"marketed","status":"active","brandName":"Integral ticagrelor","genericName":"Integral ticagrelor","companyName":"Collegium Medicum w Bydgoszczy","companyId":"collegium-medicum-w-bydgoszczy","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ticagrelor is a P2Y12 platelet receptor antagonist that inhibits platelet aggregation and reduces thrombotic events. Used for Acute coronary syndrome (ACS), Secondary prevention of thrombotic cardiovascular events.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}